Stock INVA INNOVIVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Innoviva, Inc.

Equities

INVA

US45781M1018

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
15.2 USD -1.11% Intraday chart for Innoviva, Inc. -0.39% -5.24%
24/04 Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 CI
04/03 Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Innoviva Names Stephen Basso as Finance Chief
Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee
Insider Buy: Innoviva
Innoviva Unit Says FDA Approves Xacduro for Treatment of Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Innoviva, Inc. Announces Retirement of George Bickerstaff, III, as Board Chairman
MÄRKTE USA/Wall Street dürfte Schwung des späten Vortageshandels halten
Innoviva Says FDA's Antimicrobial Drugs Advisory Committee to Convene in April to Review New Drug Application for Sulbactam-Durlobactam
Innoviva, Inc. Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
Innoviva, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Zai Lab New Drug Application for Sulbactam-Durlobactam Accepted in China
Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INVA Stock
  4. News Innoviva, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW